高级检索
当前位置: 首页 > 详情页

Salt-inducible kinase 1 is involved in high glucose-induced mesangial cell proliferation mediated by the ALK5 signaling pathway

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Tradit Chinese Med & Endocrinol, Liyuan Hosp, Wuhan 430077, Hubei, Peoples R China [2]First Peoples Hosp Jiujiang City, Jiujiang, Peoples R China [3]Huazhong Univ Sci & Technol,Tongji Hosp,Dept Gen Surg,Wuhan 430074,Peoples R China [4]Huazhong Univ Sci & Technol, Liyuan Hosp, Dept Neurol, Tongji Med Coll, Wuhan 430074, Peoples R China [5]Natl Inst Biomed Innovat, Lab Cell Signaling & Metab, Osaka, Japan
出处:
ISSN:

关键词: extracellular matrix accumulation activin receptor-like kinase 5 signaling pathway salt-inducible kinase 1 cell proliferation

摘要:
High glucose levels can induce mesangial cell proliferation and extracellular matrix (ECM) accumulation through the type I activin receptor-like kinase 5 (ALK5) signaling pathway. Salt-inducible kinase 1 (SIK1) prevents fibrosis by downregulating ALK5, while the expression level of the SIK1 protein itself is downregulated by glucose in neuronal cells following ischemia. In this study, we investigated the correlation between SIK1 and the ALK5 signaling pathway in a rat glomerular mesangial cell line (HBZY-1 cells). We found that high glucose levels downregulated the expression level of SIK1 and suppressed the phosphorylation of SIK1 at Thr-182. The downregulation of SIK1 by high glucose was accompanied by the activation of the ALK5 signaling pathway, while the overexpression of SIK1 in the HBZY-1 cells resulted in a decrease in the ALK5 protein level, as well in the levels of its downstream targets, including fibronectin and plasminogen activator inhibitor type I. In conclusion, high glucose may activate the ALK5 signaling pathway by downregulating SIK1, and SIK1 may be a protective factor against cellular proliferation and ECM accumulation in glomerular mesangial cells under high glucose conditions.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验
JCR分区:
出版当年[2011]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Tradit Chinese Med & Endocrinol, Liyuan Hosp, Wuhan 430077, Hubei, Peoples R China [2]First Peoples Hosp Jiujiang City, Jiujiang, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Tradit Chinese Med & Endocrinol, Liyuan Hosp, Wuhan 430077, Hubei, Peoples R China [*1]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Tradit Chinese Med & Endocrinol, Liyuan Hosp, 39 Lake Ave, Wuhan 430077, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:2 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)